Insurance for Anabolic Bone Agents: What You'll Actually Pay for Forteo, Tymlos, and Evenity

Why Anabolic Agents Are So Expensive

Anabolic bone drugs build new bone rather than simply slowing breakdown. This makes them the most effective class for severe osteoporosis, but the biology behind them also makes them costly to manufacture and deliver. All three approved agents are biologics or peptides requiring cold-chain shipping and specialty pharmacy handling.

Teriparatide (Forteo), the first FDA-approved bone anabolic agent, carries a wholesale acquisition cost (WAC) of roughly $3,541 per month for the 20 mcg daily injection pen [1]. Abaloparatide (Tymlos) comes in at approximately $1,980 per month for its 80 mcg daily pen [2]. Romosozumab (Evenity), a monoclonal antibody given as two subcutaneous injections once monthly, lists at about $2,850 per treatment [3].

These prices place anabolic agents in a completely different tier from oral bisphosphonates like alendronate, which cost $10 to $30 per month as generics. That price gap is the primary reason insurers gate anabolic agents behind prior authorization and step-therapy requirements. The AACE 2020 guidelines recommend anabolic-first therapy for patients at very high fracture risk, but payer policies have been slow to align with that recommendation [4].

Generic teriparatide biosimilars entered the U.S. market in late 2023. That has not eliminated prior authorization requirements, but some plans now offer lower tier placement for biosimilar teriparatide compared to brand Forteo.

Prior Authorization: The Gatekeeper for Coverage

Almost every insurer requires prior authorization before covering any anabolic bone agent. The PA process verifies that the patient meets specific clinical criteria, and the documentation burden falls heavily on the prescribing clinician. Expect the process to take 5 to 14 business days for initial determination.

Standard prior authorization criteria across most commercial plans include: a confirmed diagnosis of osteoporosis (T-score of -2.5 or lower at the spine, hip, or femoral neck), documented intolerance or inadequate response to at least one oral bisphosphonate, and evidence of high fracture risk such as a prior fragility fracture or a FRAX score exceeding intervention thresholds [5]. Some plans waive the bisphosphonate step-therapy requirement for patients with multiple vertebral fractures or a T-score below -3.0.

Medicare Part D plans typically mirror these criteria but add formulary-specific quantity limits. Evenity, for instance, is often limited to 12 monthly fills reflecting its approved treatment course of 12 doses. Forteo and Tymlos are generally authorized for 18 to 24 months [6].

Dr. Andrea Singer, Director of Bone Density Services at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has noted: "The requirement for bisphosphonate failure before accessing anabolic therapy means some of our highest-risk patients experience preventable fractures during a trial period that clinical evidence does not support" [7].

A denied PA can be appealed. First-level appeals succeed roughly 40% to 60% of the time when accompanied by a detailed letter of medical necessity that references the AACE/ACE 2020 Clinical Practice Guidelines and the patient's individualized fracture risk assessment [4].

Forteo (Teriparatide): Coverage Details and Cost Reduction

Forteo was approved in 2002 and now faces biosimilar competition. Still, brand Forteo remains widely prescribed. Its coverage pathway is well established across payers.

With commercial insurance and the Forteo Savings Card (offered by Lilly), eligible patients may pay as little as $0 per month on their copay. The savings card covers up to $6,000 per year in out-of-pocket costs and is available to commercially insured patients who are not covered by any federal or state healthcare program [8]. Without the savings card, commercially insured patients on specialty tiers typically face coinsurance of 25% to 33%, translating to $885 to $1,168 per month.

Medicare Part D enrollees cannot use manufacturer copay cards. Their costs depend on plan tier placement and whether they have reached the catastrophic coverage phase. Under the Inflation Reduction Act provisions taking effect in 2025, the annual out-of-pocket cap for Part D is $2,000 [9]. This means even without low-income subsidies, a Medicare patient's total annual spend on Forteo is capped.

Biosimilar teriparatide (such as the Pfizer-marketed version) may offer 15% to 30% savings at the pharmacy level. Ask your prescriber and plan whether the biosimilar carries a lower tier or preferred status.

Lilly's Forteo Patient Assistance Program provides free medication to uninsured patients with household income at or below 300% of the federal poverty level. Application requires proof of income and a prescription from a U.S.-licensed provider [8].

Tymlos (Abaloparatide): What Plans Actually Cover

Tymlos, manufactured by Radius Health (now Ipsen), received FDA approval in 2017. Its list price is lower than brand Forteo, but coverage patterns vary more across payers because formulary inclusion is less universal.

In the ACTIVE trial (N=2,463), abaloparatide 80 mcg daily reduced new vertebral fractures by 86% compared to placebo at 18 months, with a relative risk reduction of 43% for nonvertebral fractures [10]. These data support PA approval requests, but some insurers still consider Tymlos non-preferred relative to teriparatide.

The Tymlos Copay Card reduces out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. Maximum annual benefit varies by program year but has historically covered up to $6 to 000 in copay or coinsurance costs. Patients must not be enrolled in Medicare, Medicaid, Tricare, or any other federal program to qualify [2].

For uninsured patients, Ipsen offers a Patient Assistance Program. Income thresholds are typically at or below 400% of the federal poverty level, though exact criteria should be confirmed through the program's intake process. A specialty pharmacy coordinator can initiate enrollment.

Evenity (Romosozumab): The Most Complex Coverage Picture

Evenity is the newest anabolic agent (approved 2019) and often the hardest to get covered. It is a sclerostin inhibitor, meaning it both builds bone and reduces resorption simultaneously. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fracture risk by 27% compared to alendronate alone at 24 months [11]. That dual mechanism comes with a notable caveat: the FDA label includes a boxed warning about potential cardiovascular risk, and this warning gives some payers an additional rationale for restrictive coverage.

Monthly treatment with Evenity consists of two 105 mg injections (210 mg total) administered in a healthcare setting. The list price of approximately $2,850 per month means a full 12-month course costs roughly $34,200 at WAC [3].

Commercial plans that cover Evenity nearly always require prior authorization with documentation of: T-score of -2.5 or lower, high fracture risk or prior fragility fracture, and failure of or contraindication to bisphosphonate therapy. Some plans add the additional criterion that the patient must not have had a myocardial infarction or stroke within the preceding 12 months, reflecting the boxed warning.

The Evenity Co-pay Program (Amgen) can reduce costs to $0 per month for commercially insured patients, with an annual cap of up to $12 to 000 in copay assistance [3]. This higher assistance ceiling reflects the drug's higher cost.

Medicare coverage is available but places Evenity on specialty tiers. With the $2,000 annual Part D out-of-pocket cap, Medicare beneficiaries have more predictable exposure than in prior years when catastrophic coverage still required 5% coinsurance [9].

The 2020 AACE guidelines specifically note that romosozumab should be considered as initial therapy for patients at very high fracture risk, citing the ARCH and FRAME trials [4]. Including this guideline language in PA submissions and appeals strengthens the clinical argument.

Denosumab (Prolia): The Anti-Resorptive Comparator

Prolia is not an anabolic agent. It is a RANK ligand inhibitor that slows bone breakdown. But because "cost of Prolia" is frequently searched alongside anabolic agents, the comparison matters for patients and prescribers deciding between drug classes.

Prolia (denosumab 60 mg) is administered as a subcutaneous injection every 6 months. Its list price is approximately $1,900 per injection, or $3,800 per year [12]. Coverage is generally easier to obtain than for anabolic agents because Prolia does not carry step-therapy requirements through a prior bisphosphonate trial at most plans. Many commercial plans cover Prolia under the medical benefit (Part B in Medicare) rather than the pharmacy benefit, which changes the cost-sharing structure.

In the FREEDOM trial (N=7,868), denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 3 years compared to placebo [13]. These are strong numbers, but they do not match the bone-building capacity of anabolic agents in patients with very severe disease.

A key coverage consideration: Prolia requires indefinite use or transition to another antiresorptive after discontinuation, because stopping denosumab causes rapid bone loss and rebound vertebral fractures [14]. This long-term cost trajectory can make anabolic-first strategies more cost-effective over a treatment lifetime, particularly when the anabolic course is finite (12 to 24 months) and followed by an inexpensive generic bisphosphonate.

Step Therapy and Sequencing: How to Build a Winning PA Case

The strongest prior authorization submissions pair clinical guidelines with patient-specific data. A formulaic approach works well.

Start the PA letter with the patient's diagnosis and fracture risk profile: DXA T-scores, FRAX 10-year probability, fracture history, and any secondary causes of bone loss such as glucocorticoid use or aromatase inhibitor therapy. Then document step-therapy compliance or exemption. If the patient tried alendronate or risedronate and experienced GI intolerance, include specific dates and adverse events. If the patient has multiple vertebral fractures or a T-score below -3.0, cite the AACE very-high-risk category that supports anabolic-first treatment [4].

Reference the specific clinical trial supporting the requested drug. For Forteo, cite the Neer et al. 2001 trial (N=1,637) showing 65% reduction in vertebral fractures [15]. For Tymlos, cite ACTIVE [10]. For Evenity, cite ARCH [11] or FRAME (N=7,180), which demonstrated 73% reduction in new vertebral fractures at 12 months compared to placebo [16].

Include a statement on cardiovascular risk assessment if requesting Evenity. Noting the absence of prior MI, stroke, or uncontrolled hypertension directly addresses the boxed warning concern.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a lead investigator on multiple romosozumab trials, has stated: "The evidence for anabolic-first therapy in very high-risk patients is now strong enough that step-through-bisphosphonate requirements represent a payer policy gap, not a clinical evidence gap" [7].

If the first PA is denied, file a formal appeal within the plan's specified timeframe (usually 30 to 60 days). Include a peer-to-peer review request. Peer-to-peer calls, where the prescriber speaks directly with the plan's medical director, overturn denials at higher rates than written appeals alone.

Patient Assistance Programs: A Safety Net for the Uninsured

All three anabolic agents and Prolia have manufacturer-sponsored patient assistance programs (PAPs) that provide free medication to qualifying uninsured or underinsured patients.

Forteo's PAP (Lilly Cares) requires household income at or below 300% of the federal poverty level, no insurance coverage for the medication, and U.S. residency [8]. Tymlos Cares (Ipsen) uses a 400% FPL threshold. Amgen Safety Net Foundation covers both Evenity and Prolia for patients at or below 300% FPL with no other coverage options [3].

Application processing takes 2 to 4 weeks. Specialty pharmacies affiliated with these programs handle enrollment and can often ship medication directly to the patient or provider office once approved.

State Pharmaceutical Assistance Programs (SPAPs) in states like New York, Pennsylvania, and New Jersey may provide supplemental coverage or copay assistance for Medicare beneficiaries who exceed income limits for Low-Income Subsidy (LIS) but still face high out-of-pocket costs. Eligibility varies by state.

The $2,000 annual Part D out-of-pocket maximum under the Inflation Reduction Act substantially changes the math for Medicare patients as of 2025. For most beneficiaries on a single anabolic agent, total annual pharmacy spending will hit the cap within 1 to 3 months, after which remaining monthly fills incur no additional cost [9].

Real-World Coverage Rates Across Plan Types

Coverage for anabolic bone agents is not uniform. Plan type, formulary design, and geographic region all influence what patients pay.

Large employer-sponsored commercial plans cover Forteo and Tymlos at rates exceeding 80% when PA criteria are met, according to formulary analysis data from Managed Markets Insight and Technology (MMIT). Evenity coverage is slightly lower, around 70% to 75%, partly due to its newer status and the cardiovascular boxed warning [6].

Medicare Part D coverage is near-universal for all three agents on the specialty tier, but cost-sharing before reaching the out-of-pocket cap can be steep. The initial coverage phase typically requires 25% to 33% coinsurance on specialty drugs.

Medicaid coverage varies by state. Many state Medicaid programs cover Forteo and Prolia but have not yet added Evenity to preferred drug lists. Fee-for-service Medicaid patients may need to go through an exceptions process.

Tricare covers all three anabolic agents through its pharmacy benefit with prior authorization. Active-duty family members and retirees should use the Tricare formulary search tool or contact Express Scripts for specific tier and copay information.